Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.51 |
| ▸ | CKS1B | P61024 | 2/20 | 0.50 |
| ▸ | SKP1 | P63208 | 2/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3442685 | 0.85 | CKS1B (0.68) | USP30CKS1BSKP1SKP2GPR119 | |
| SCHEMBL31274442 | 0.82 | PDE10A (0.50) | PDE10AUSP30GPR119ACACBHCRTR1 | |
| SCHEMBL22795888 | 0.82 | PDE10A (0.50) | PDE10AUSP30GPR119ACACBHCRTR1 | |
| SCHEMBL928501 | 0.82 | PDE10A (0.50) | PDE10AUSP30GPR119ACACBHCRTR1 | |
| SCHEMBL30205688 | 0.82 | PDE10A (0.50) | PDE10AUSP30CKS1BSKP1SKP2 | |
| SCHEMBL22495526 | 0.82 | GPR119 (0.70) | PDE10AGPR119 | |
| SCHEMBL29461508 | 0.82 | GPR119 (0.70) | PDE10AGPR119 | |
| SCHEMBL22495527 | 0.82 | GPR119 (0.70) | PDE10AGPR119 | |
| SCHEMBL15663026 | 0.82 | CHRNA7 (0.60) | PDE10AUSP30GPR119 | |
| SCHEMBL6330678 | 0.82 | CHRNA7 (0.60) | PDE10AUSP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | ABBOTT LABORATORIES | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | CHRNA7, CHRNA1, CHRNA5 | PDE10A 1088/4885USP30 4503/4885CKS1B 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.